(Q37861207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

Cancer stem cells: the development of new cancer therapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

main subject

neoplastic stem cells

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Roberto Scatena

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Alessandro Pontoglio

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Bruno Giardina

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

30 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

875-892

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463158%20AND%20SRC:MED&resulttype=core&format=json

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Stem cell concepts renew cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Cancer stem cells: mirage or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Heterogeneity in cancer: cancer stem cells versus clonal evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Cancer stem cells: the other face of Janus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Cancer stem cell: target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Tyrosine kinases as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Recent advances on the role of CD40 and dendritic cells in immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Assessing the risk to health care staff from long-term exposure to anticancer drugs - the case of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The emerging role of EpCAM in cancer and stem cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Tyrosine kinase inhibitors: the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

HER2 as a cancer stem-cell target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Wnt signalling in stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Simulations of a specific inhibitor of the dishevelled PDZ domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Hedgehog signalling in endocrine development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Targeting Hedgehog--a cancer stem cell pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Novel investigational drugs for basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Notch signaling in development and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Targeting Notch to target cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Notch signaling in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Notch signaling: emerging molecular targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Therapeutic antibody targeting of individual Notch receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Inhibition of the PI3K pathway: hope we can believe in?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Telomere dysfunction and tumour suppression: the senescence connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The difficulty of targeting cancer stem cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Sunitinib rechallenge in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Targeting RET Receptor Tyrosine Kinase Activation in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Tumour stem cell-targeted treatment: elimination or differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Differentiation therapy of leukemia: 3 decades of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Histone deacetylase inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Glioblastoma stem-like cells give rise to tumour endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780

Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.573780